Plain-English translation of NCT03048266 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is looking for early warning signs in the blood that can help doctors predict which people with MEN1 syndrome will develop aggressive pancreatic tumors. Researchers will analyze blood samples to identify special molecules and genetic markers that might signal tumor risk. The goal is to create a better way to monitor and care for people with MEN1.
People with MEN1 syndrome often develop pancreatic tumors, but it's hard to know in advance which tumors will be aggressive and dangerous. This study aims to find blood-based clues that can help doctors identify high-risk patients earlier, so they can receive better monitoring and treatment before serious problems develop.
You likely qualify if…
You likely don't qualify if…
You would donate blood samples as part of your regular follow-up care for MEN1. Researchers will analyze your blood to look for specific molecules and genetic markers that might predict tumor behavior. The study involves two main groups: people whose pancreatic tumors have been aggressive and people whose tumors have not been aggressive, so doctors can compare the blood findings between the two groups.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Enrollment target
~629 participants
Started
November 2015
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in May 2019.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nancy D. Perrier, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.